| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
ChiCTR2000038249: Application of Toripalimab combined with TKI in preoperative treatment of patients with advanced renal carcinoma |
|
|
| Recruiting | 4 | 25 | China | Toripalimab combined with TKI | SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine ; SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine, Shanghai Junshi Biomedical Technology Co., LTD | Renal cell carcinoma | | | | |
ChiCTR2100045556: A multicenter, open-label, randomized controlled clinical trail of PD-1 inhibitor (Toripalimab) combined with TPF chemotherapy for neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma |
|
|
| Recruiting | 4 | 100 | China | Toripalimab +Docetaxel + Cisplatin + Fluorouracil ;Docetaxel + Cisplatin + Fluorouracil | Sichuan Cancer Hospital ; Sichuan Cancer Hospital, TopAlliance Biosciences Inc. | Locally advanced head and neck squamous cell carcinoma | | | | |
TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer |
|
|
| Not yet recruiting | 4 | 100 | NA | Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin | Coherus Biosciences, Inc. | Nasopharyngeal Cancer Recurrent | 12/27 | 12/27 | | |
2020-004437-20: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC) |
|
|
| Ongoing | 3 | 519 | Europe | Toripalimab, LENVIMA, TAB001 and JS001, Solution for infusion, Capsule, hard, LENVIMA | Shanghai Junshi Biosciences Co., Ltd, Shanghai Junshi Biosciences Co., Ltd., Shanghai Junshi Biosciences Co., Ltd | advanced hepatocellular carcinoma (HCC), liver cancer, Diseases [C] - Cancer [C04] | | | | |
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 3 | 194 | RoW | Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI | Hutchison Medipharma Limited | Advanced Neuroendocrine Carcinoma | 05/25 | 05/25 | | |
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma |
|
|
| Recruiting | 3 | 452 | RoW | RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin | RemeGen Co., Ltd. | Urothelial Carcinoma, HER2-expressing | 12/26 | 04/28 | | |
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2/3 | 130 | RoW | RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets | RemeGen Co., Ltd. | Gastric Cancer | 07/24 | 07/25 | | |
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer |
|
|
| Ongoing | 2 | | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HR-negative, HER2-low breast cancer | | | | |
RC48-C026, CTR20232220: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab versus pertuzumab with or without toripalimab in the neoadjuvant treatment of patients with HER2-positive breast cancer |
|
|
| Ongoing | 2 | 80 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, Perjeta (pertuzumab) - Roche | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-positive breast cancer | | | | |
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g |
|
|
| Recruiting | 2 | 90 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma | | | | |
ChiCTR1900023710: Toripalimab combined with capecitabine for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy: a prospective, single-arm, phase II trial |
|
|
| Not yet recruiting | 2 | 23 | China | Toripalimab combined with capecitabine | Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University ; Sun Yat-sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents six courses of Toripalimab for each patient. | Nasopharyngeal Carcinoma | | | | |
ChiCTR2000033668: TACE and Lenvatinib Plus PD-1 Antibody Versus TACE Plus Lenvtinib for Advanced HCC: a Single-Centre Randomised Controlled Trial |
|
|
| Not yet recruiting | 2 | 80 | China | TACE+Lenvatinib plus toripalimab, an inhibitor of PD1 ;TACE+Lenvatinib | Eastern Hepatobiliary Surgery Hospital ; Eastern Hepatobiliary Surgery Hospital, Shanghai Junshi Biopharmaceutical Technology Co., Ltd. | Advanced unresectable HCC | | | | |
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Bevacizumab, QL1101, Tripleitriumab, JS001 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd. | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 09/21 | 02/22 | | |
ChiCTR2000033506: A phase II trial of TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy for patients with local advanced laryngeal/hypopharyngeal carcinoma |
|
|
| Recruiting | 2 | 43 | China | TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy | Sun Yat-Sen University Cancer Center ; Level of the institution：, Shanghai Junshi Biosciences Co., Ltd. | Laryngeal carcinoma /hypopharyngeal carcinoma | | | | |
ChiCTR2100043981: Toripalimab Combined with Concurrent Chemoradiotherapy in Stage IV Hypopharyngeal Carcinoma without Distant Metastasis |
|
|
| Recruiting | 2 | 76 | China | Toripalimab combined with concurrent chemotherapy ;concurrent chemotherapy | National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC ; Level of the institution：, Suzhou Zhonghe Biomedical Technology Co., Ltd | hypopharyngeal cancer | | | | |
ChiCTR2000039371: Evaluating the efficacy and safety of Teriprizumab injection (JS001) combined with lenvatinib as first-line treatment in patients with Advanced Hepatocellular Carcinoma: a single-arm, open-label clinical trial. |
|
|
| Recruiting | 2 | 30 | China | Teriprizumab injection + Lenvatinib | Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guangxi Medical University ; Affiliated Cancer Hospital of Guangxi Medical University, Shanghai Junshi Biomedical Technology Co., Ltd. | Hepatocellular Carcinoma | | | | |
| Completed | 2 | 50 | RoW | GS+Toripalimab | Shanghai Zhongshan Hospital, Shanghai Junshi Bioscience Co., Ltd., OrigiMed | Biliary Tract Cancer | 12/21 | 03/22 | | |
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 2 | 248 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Hutchison Medipharma Limited | Advanced Solid Tumors | 02/23 | 02/23 | | |
ChiCTR2100046715: A single-arm, prospective, open-label, phase II clinical trial of toripalimab in combination with induction chemotherapy and concurrent chemoradiation as first-line treatment for advanced/metastatic esophageal carcinoma |
|
|
| Recruiting | 2 | 30 | China | toripalimab in combination with induction chemotherapy and concurrent chemoradiation | Sichuan Cancer Hospital & Institute ; Sichuan Cancer Hospital & Institute, Shanghai Junshi Bioscience Co., Ltd. | Esophagus cancer | | | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001 | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 12/27 | | |
NCT06178159: DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Disitamab Vedotin Injection, DV,RC48-ADC, Pertuzumab Injection, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 12/24 | 06/25 | | |
YH003004, NCT05031494: A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers |
|
|
| Active, not recruiting | 2 | 129 | US, RoW | YH003, Toripalimab, Nab-paclitaxel, Gemcitabine | Eucure (Beijing) Biopharma Co., Ltd | Melanoma, Pancreatic Ductal Adenocarcinoma | 01/24 | 01/24 | | |
NCT06283121: A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab | China Medical University, China, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Gastric Cancer, Metastatic | 11/27 | 11/27 | | |
NCT06389006: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 79 | RoW | Disitamab Vedotin for Injection, RC48, Toripalimab, JS001, Epirubicin, Cyclophosphamide, CTX | RemeGen Co., Ltd. | Breast Cancer | 06/25 | 12/26 | | |
ChiCTR2100045147: Radiotherapy combined with Toripalimab in the treatment of stage I/II extranodal nasal NK/T cell lymphoma with poor response to chemotherapy: a single-arm, multicenter study |
|
|
| Recruiting | 2 | 41 | China | Radiotherapy + Toripalimab | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, Shanghai Junshi Biosciences Co., Ltd；West China Hospital, Sichuan University | NK/T lymphoma | | | | |
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 40 | RoW | RC48-ADC, JS001 | RemeGen Co., Ltd. | Muscle Invasive Bladder Carcinoma | 06/24 | 02/25 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT05386888: A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC |
|
|
| Active, not recruiting | 2 | 65 | RoW | GFH018, Toripalimab, Paclitaxel, Carboplatin, Cisplatin, Pemetrexed, Thoracic Radiation Therapy (TRT) | Zhejiang Genfleet Therapeutics Co., Ltd. | NSCLC, Stage III | 10/24 | 01/25 | | |
NCT05479045: A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients |
|
|
| Suspended | 2 | 24 | US | NY-ESO-1 Peptide vaccine, Toripalimab-tpzi, LOQTORZI | Georgetown University, United States Department of Defense, Coherus Biosciences, Inc. | Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3 | 11/25 | 11/26 | | |
NCT05173246: JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection, nab-paclitaxel, Paclitaxel for injection (Albumin Bound), Cisplatin, Cisplatin for injection, Carboplatin, Carboplatin for injection | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. | Esophageal Small Cell Carcinoma | 11/24 | 11/25 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
TORAN, ChiCTR2100054901: A phase II trial of anlotinib and toripalimab as maintenance therapy in patients with advanced soft tissue sarcoma after anthracycline-based chemotherapy |
|
|
| Recruiting | 2 | 50 | China | Anlotinib + Toripalimab | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, West China Hospital, Sichuan University; Shanghai Junshi Biosciences Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft tissue sarcoma | | | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 246 | RoW | Axitinib plus Toripalimab, nephrectomy | ZHOU FANGJIAN, Pfizer | Renal Cell Carcinoma, Neoadjuvant | 07/25 | 03/26 | | |
NCT06124963: A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations |
|
|
| Recruiting | 2 | 20 | RoW | WX390, WXFL10030390, Toripalimab | Shanghai Jiatan Pharmatech Co., Ltd | Gastric Type Adenocarcinoma (GAS) With STK11 Mutation | 12/25 | 12/25 | | |
NCT06105008: Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 80 | RoW | Disitamab Vedotin, RC48-ADC, DV, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Neoplasms | 12/25 | 04/26 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |
ChiCTR2300067960: A single-arm, phase II trial about adjuvant Toripalimab treating locally advanced patients with head and neck squamous carcinoma who achieved complete pathological response after neoadjuvant chemoimmunotherapy and surgery |
|
|
| Not yet recruiting | 2 | 25 | China | Toripalimab, 240mg Q3W, 8 cycles | Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, Junshi Biosciences (Shanghai) Co.,Ltd | Head and neck squamous carcinoma | | | | |
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study |
|
|
| Recruiting | 2 | 26 | China | The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1000mg/m2), Cisplatin, intravenous infusion, day 1 (80mg/ m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study. | Dongguan People's Hospital ; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd | nasopharyngeal carcinoma | | | | |
ChiCTR2200056870: An open, multicenter, single-arm, phase II study evaluating triplimumab injection (JS001) combined with chemotherapy for neoadjuvant treatment of gastric/gastroesophageal junction cancer |
|
|
| Not yet recruiting | 2 | 40 | China | Toripalimab injection (JS001) combined with capecitabine and oxaliplatin | Guangdong Provincial People's Hospital ; Guangdong Provincial People's Hospital, Tririplizumab injection (JS001) was provided free of charge by Shanghai Junshi Biomedical Technology Co., LTD. | gastric/gastroesophageal junction carcinoma | | | | |
ChiCTR2100042602: Toripalimab combined with IMRT for nasopharyngeal carcinoma with unsatisfactory response or detectable EBV DNA after induction chemotherapy: a prospective, single-arm, phase II clinical trial |
|
|
| Recruiting | 2 | 34 | China | Toripalimab combined with IMRT (toripalimab 240mg every 3 weeks for 1 year or until confirming disease progression or unacceptable toxicity occurring) | Sun Yat-Sen University Cancer Center ; Sun Yat-Sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents 17 courses of toripalimab | nasopharyngeal carcinoma | | | | |
NCT04721223: JAB-3068 Activity in Adult Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1b/2a | 118 | RoW | JAB-3068, PD1 inhibitor | Jacobio Pharmaceuticals Co., Ltd., AbbVie | Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 02/22 | 10/22 | | |
RC108-C004, CTR20232828: An open-label, single-arm, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, efficacy, and pharmacokinetic profile of RC108 in combination with toripalimab in patients with c-Met-expressing advanced solid tumors |
|
|
| Ongoing | 1b/2 | 178 | China | RC108 - Rongchang Pharma | Remegen Biopharmaceutical (Yantai) Co., Ltd | C-MET-expressing advanced solid tumors | | | | |
NCT05103917: A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC |
|
|
| Enrolling by invitation | 1/2 | 24 | RoW | X4P-001, Toripalimab Injection | Abbisko Therapeutics Co, Ltd | Triple Negative Breast Cancer | 11/22 | 05/23 | | |
ChiCTR2100048891: Study of the safety and efficacy of donafenib combined with toripalimab in patients with non-MSI-H metastatic colorectal cancer |
|
|
| Not yet recruiting | 1/2 | 35 | China | Donafenib + Toripalimab | Sichuan Cancer Hospital ; Sichuan Cancer Hospital, Suzhou Zelgen Biopharmaceuticals Co., Ltd. | colorectal cancer | | | | |
NCT04503902: Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 46 | RoW | Donafenib Tosilate Tablets, Donafenib, Toripalimab Injection, JS001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Advanced Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 07/24 | 12/24 | | |
NCT04914286: A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 148 | RoW | GFH018, Toripalimab | Zhejiang Genfleet Therapeutics Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/23 | | |
NCT06208410: A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors |
|
|
| Recruiting | 1/2 | 306 | RoW | JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets, Toripalimab Injection, Paclitaxel for Injection (Albumin Bound), Fluzoparib Capsules, Pyrotinib Maleate Tablets, Capecitabine Tablets | Risen (Suzhou) Pharma Tech Co., Ltd. | Advanced Solid Tumors | 02/26 | 02/26 | | |
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 20 | RoW | LM-302, Toripalimab, Tuoyi | LaNova Australia Pty Limited | Advanced Solid Tumor | 11/23 | 11/23 | | |
IN10018-010, NCT05830539: IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients |
|
|
| Active, not recruiting | 1/2 | 240 | RoW | IN10018+PLD, IN10018 and Doxorubicin Hydrochloride Liposome Injection, IN10018+PLD+Toripalimab, IN10018 and Doxorubicin Hydrochloride Liposome Injection and Toripalimab | InxMed (Shanghai) Co., Ltd. | Locally Advanced or Metastatic Solid Tumors | 03/24 | 12/24 | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06410703: CAN1012 Combined With PD-1 in Patients With Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 71 | RoW | CAN1012, Toripalimab | Canwell Biotech Limited | Advanced Solid Tumor | 05/25 | 05/26 | | |
NCT05173142: HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 141 | RoW | HMPL-453, gemcitabine and cisplatin, toripalimab, Docetaxel | Hutchison Medipharma Limited | Solid Tumor | 09/24 | 08/25 | | |
NCT05615974: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors |
|
|
| Suspended | 1/2 | 145 | RoW | LM101, Toripalimab, Rituximab, Envafolimab | LaNova Medicines Limited | Malignant Tumors | 12/24 | 08/25 | | |
| Recruiting | 1/2 | 84 | RoW | KD6001, Toripalimab, JS001 | Shanghai Kanda Biotechnology Co., Ltd. | Melanoma | 12/24 | 12/25 | | |
NCT06117566: A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 100 | RoW | WX390, WXFL10030390, Toripalimab | Shanghai Jiatan Pharmatech Co., Ltd | Solid Tumor | 03/25 | 03/25 | | |
NCT05804526: A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 82 | RoW | RC88, Sintilimab Injection, Sintilimab | RemeGen Co., Ltd. | Advanced Solid Tumours | 05/25 | 12/25 | | |
NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 392 | RoW | LM-108, Toripalimab | LaNova Medicines Limited | Advanced Solid Tumor | 07/25 | 10/25 | | |
NCT05821933: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC |
|
|
| Recruiting | 1/2 | 106 | RoW | RC108, Furmonertinib, Toripalimab | RemeGen Co., Ltd. | NSCLC | 09/25 | 09/26 | | |
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 22 | US | CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001 | Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 01/26 | 01/26 | | |
NCT05955105: A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies |
|
|
| Recruiting | 1/2 | 200 | RoW | ILB-2109, Toripalimab | Innolake Biopharm | Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma | 01/26 | 07/26 | | |
NCT06038396: A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 64 | RoW | RC118, RC118 for injection, Toripalimab, Toripalimab for injection, JS001 | RemeGen Co., Ltd. | Advanced Solid Tumor | 02/26 | 08/26 | | |
NCT06079112: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer |
|
|
| Not yet recruiting | 1/2 | 100 | RoW | 9MW2821, 9MW2821 injection, Toripalimab, Toripalimab injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/27 | | |
ACE-COMBO-02, CTR20222247: A Phase I clinical study to evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal anti-AS269 conjugate (ARX788) in combination with toripalimab in patients with HER2-expressing or mutated advanced solid tumors |
|
|
| Recruiting | 1 | 85 | China | anvatabart opadotin (ARX788) - Ambrx, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci | Zhejiang Xinma Biopharmaceutical Co., Ltd | HER2-expressing or mutated advanced solid tumors | | | | |
| Completed | 1 | 134 | RoW | CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Solid Tumor | 03/21 | 01/24 | | |
| Terminated | 1 | 18 | RoW | LM-061, Kinase inhibitor, Toripalimab | LaNova Medicines Limited | Advanced Tumours | 07/22 | 12/22 | | |
NCT03474640: Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies |
|
|
| Active, not recruiting | 1 | 198 | US | Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody, TAB001, JS001 | Shanghai Junshi Bioscience Co., Ltd., TopAlliance Biosciences, Inc., Iqvia Pty Ltd | Advanced Malignancies | 08/22 | 08/23 | | |
NCT05369286: A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 28 | RoW | "MAX-40279-01" and "Toripalimab" | Maxinovel Pty., Ltd. | Solid Tumor | 05/23 | 08/23 | | |
ChiCTR2200058936: Phase I clinical study on the safety and effectiveness of ECAR-T (Enhanced receptor and chimeric antigen receptor - modified PD1-positive T cell) in the treatment of CD19-positive relapsed or refractory non-Hodgkin's lymphoma |
|
|
| Recruiting | 1 | 29 | China | Based on the results of the dose escalation test, the recommended dose for the extension phase is determined ;Chemotherapy pretreatment +ECAR-T (1x10^6) ;Chemotherapy pretreatment +ECAR-T (3.3x10^6) ;Chemotherapy pretreatment +ECAR-T (10x10^6) ;Chemotherapy preconditioning+Toripalimab+ECAR-T (3.3x10^6) ;Chemotherapy preconditioning+Toripalimab+ECAR-T (10x10^6) | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, CHINEO MED (BEIJING) CO., LTD. | CD19-positive refractory relapsed non-Hodgkin's lymphoma | | | | |
NCT05040932: Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy |
|
|
| Completed | 1 | 8 | RoW | YH004 | Eucure (Beijing) Biopharma Co., Ltd | Cancer | 07/23 | 07/23 | | |
ADG116-1003, NCT04501276: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients |
|
|
| Active, not recruiting | 1 | 72 | US, RoW | ADG116, ADG106, anti PD1 drug | Adagene Inc | Advanced/Metastatic Solid Tumors | 07/24 | 08/24 | | |
NCT05451407: Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 50 | RoW | TQB2618 injection, Toripalimab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Melanoma | 10/23 | 12/23 | | |
NCT05167071: HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003, Toripalimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 10/23 | 06/24 | | |
NCT04727164: Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003 and Triprilimab, HBM4003 | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 11/23 | 11/23 | | |
ChiCTR2200066118: A Clinical Pharmacology Exploratory Study of RNA tumor vaccine injection alone or combined with PD-1 inhibitors in the treatment of advanced melanoma |
|
|
| Recruiting | 1 | 15 | China | reRNA-Melanoma Vaccine/ PD-1 Terepril Monoclonal Antibody Injection | The First Affiliated Hospital of Nanyang Medical College ; The First Affiliated Hospital of Nanyang Medical College, Jiangsu Leeway Biological Technology Co.Ltd. | advanced melanoma | | | | |
NCT04605185: Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 1 | 18 | RoW | Donafenib Tosilate Tablets, Toripalimab Injection, JS001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unresectable Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma |
|
|
| Recruiting | 1 | 88 | RoW | LBL-007, Toripalimab, Axitinib Tablets | Nanjing Leads Biolabs Co.,Ltd | Advanced Melanoma | 08/24 | 12/24 | | |
ChiCTR2100054307: A randomized controlled study of single-dose pharmacokinetics of toripalimab injection in hepatic arterial infusion versus intravenous infusion in malignant melanoma liver metastases |
|
|
| Recruiting | 1 | 16 | China | perfusion toripalimab injection ;infusion of toripalimab intravenously | Sun Yat-Sen University Cancer Center ; Sun Yat-Sen University Cancer Center, Shanghai Junshi Biosciences Co., Ltd. | malignant melanoma | | | | |
NCT06283134: A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer |
|
|
| Not yet recruiting | 1 | 40 | NA | BioTTT001 hepatic artery infusion, toripalimab, regorafenib | China Medical University, China, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Colorectal Cancer Metastatic | 12/27 | 12/27 | | |
| Recruiting | 1 | 260 | US, RoW | CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi® | Coherus Biosciences, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 12/25 | 08/26 | | |
ChiCTR2300071740: A prospective study of reRNA™ HPV tumor vaccine alone or in combination with immune checkpoint inhibitors in patients with HPV16/18-positive unresectable recurrent or metastatic solid tumors |
|
|
| Recruiting | 1 | 12 | China | reRNA-HPV tumor vaccine/PD-1 toripalimab injection | The First Affiliated Hospital of Nanyang Medical College ; The First Affiliated Hospital of Nanyang Medical College, Jiangsu Leeway Biological Technology Co., Ltd. | HPV16/18-positive unresectable recurrent or metastatic solid tumors | | | | |
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1 | 67 | NA | HBM4003 and Triprilimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 05/24 | 05/24 | | |
NCT04991506: A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 82 | RoW | ES102, JS001, Toripalimab | Elpiscience Biopharma, Ltd., Shanghai Junshi Bioscience Co., Ltd. | Solid Tumor, Neoplasms, Malignant Tumor | 05/24 | 06/25 | | |
NCT06389526: A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 48 | NA | CHS-1000, Toripalimab, Loqtorzi, Toripalimab-tpzi | Coherus Biosciences, Inc. | Advanced or Metastatic Solid Tumors | 01/28 | 01/28 | | |
NCT04280341: JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | RC48-ADC in combinaton with JS001 | Peking University, RemeGen Co., Ltd. | HER2-Positive Solid Tumors | 12/24 | 12/24 | | |
| Recruiting | N/A | 30 | China | Anlotinib Hydrochloride Capsules Combined With Toripalimab Injection | The Second Affiliated Hospital of Hai'nan Medical University ; The Second Affiliated Hospital of Hainan Medical University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular carcinoma | | | | |
ChiCTR2000029500: An Open Label, Single-arm Study for Effect of Neoadjuvant Toripalimab (JS001) Before Cystectomy in the treatment of Patients With Muscle-invasive Urothelial Bladder Cancer. |
|
|
| Completed | N/A | 20 | China | Neoadjuvant Toripalimab Before Cystectomy | Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ; Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, TopAlliance Biosciences Inc. | Urothelial Bladder Cancer | | | | |
ChiCTR2000035237: A single arm, single center clinical study of Toripalimab combined with paclitaxel and platinum as neoadjuvant therapy on patients with esophageal squamous cell carcinoma at clinical stage of T2-T3/N0-N1/M0 |
|
|
| Recruiting | N/A | 30 | China | Toripalimab combined with paclitaxel and platinum as neoadjuvant therapy | Army Medical Center of PLA ; Army Characteristic Medical Center of the People's Liberation Army of China, Toripalimab will be provided by Shanghai Junshi Biology Co., Ltd. | Esophageal squamous carcinoma | | | | |
ChiCTR1900025796: Chemotherapy plus Toripalimab Augmented by Hypofractionated Radiotherapy as First Line Treatment for Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | N/A | 36 | China | Chemotherapy plus Toripalimab Augmented by Hypofractionated Radiotherapy | Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Junshi Biopharmaceutical Technology Co., Ltd. | Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | | | | |
ChiCTR2000028979: A Prospective, Single-Arm Phase II Cclinical Trial of Toripalimab Combined With Chemotherapy for Neoadjuvant Treatment Followed by Toripalimab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Bladder Cancer |
|
|
| Not yet recruiting | N/A | 59 | China | Toripalimab combined with chemotherapy for Neoadjuvant Treatment | West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Toripalimab is rovided by TopAlliance Biosciences Inc. | muscle-invasive urothelial bladder cancer | | | | |
ChiCTR2300073041: A prospective, non-randomized, open, controlled clinical study comparing Toripalimab adjuvant therapy with clinical observation in resected subjects with esophageal squamous cell carcinoma |
|
|
| Completed | N/A | 60 | China | Postoperative Toripalimab therapy ;N/A | Beijing Cancer Hospital ; Beijing Cancer Hospital, Shanghai Junshi Biosciences Co.,Ltd | esophagus cancer | | | | |
ChiCTR2100049320: Toripalimab Combined with Targeted + TACE and Radiotherapy in the Treatment of Inoperable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 20 | China | TACE was treated 2-3 times for 8-12 weeks; Toripalimab combined with radiotherapy for 6 weeks; Toripalimab was repeated every 3 weeks until the end of cycle 9 or PD or other early termination occurred. The dosage of targeted drugs is selected by researchers according to the patient's situation. | Shandong Cancer Hospital ; Shandong Cancer Hospital, Shanghai Junshi Biomedical Technology Co., Ltd | Hepatocellular carcinoma | | | | |
ChiCTR2100052283: Clinical study of mRNA personalized tumor vaccine encoding neoantigen combined with toripalimab injection in the treatment of advanced non-small cell lung cancer |
|
|
| Not yet recruiting | N/A | 20 | China | mRNA personalized tumor vaccine encoding neoantigen + toripalimab injection ;mRNA personalized tumor vaccine encoding neoantigen + toripalimab injection | Shanghai Pulmonary Hospital ; Shanghai Pulmonary Hospital, Stemirna Therapeutics Co., Ltd. | Advanced Non-small Cell Lung Cancer | | | | |
ChiCTR2300069123: An open and single-arm study to evaluate the safety and efficacy of SMET12 combined with toripalimab in EGFR positive patients with Advanced Solid Tumors |
|
|
| Not yet recruiting | N/A | 60 | China | SMET12 combined with toripalimab | Fujian Cancer Hospital ; Fujian Cancer Hospital, Zhejiang Shimai Pharmaceutical Co.,Ltd. | EGFR positive Advanced Solid tumors | | | | |